Australia's Pharmaceutical Benefits Advisory Committee (PBAC) is launching a comprehensive review of all multiple sclerosis medicines covered by the national health system, examining how treatments are being used, what clinical evidence supports them, and whether current listings match contemporary medical guidelines. The review will include all PBS-listed medicines for relapsing-remitting MS, along with rituximab, which is sometimes used to treat the condition.

What Is the PBAC Review and Why Does It Matter?

The Department of Health, Disability and Ageing is conducting this review through the Post-market Review Framework, with a final report requested for the PBAC's December 2026 meeting. The process will examine how treatments are actually being prescribed on the PBS, whether new clinical evidence comparing different treatments has emerged since previous reviews, and whether current listings remain aligned with how neurologists and MS specialists practice medicine today.

For people living with MS, this review matters because it could influence which treatments remain accessible and affordable through Australia's Pharmaceutical Benefits Scheme. The review will include input from both clinicians and patients, ensuring that real-world experiences shape the outcome.

How Will the Review Process Work?

The PBAC will commence a six-week public consultation in mid-August 2026, with evidence review continuing through November 2026. The timeline includes several key milestones:

• Public Consultation: A six-week period beginning mid-August 2026 for stakeholders to submit feedback and evidence
• Evidence Review Period: August through November 2026, during which the PBAC examines clinical data and patient input
• Draft Report Consideration: The PBAC will review the draft report on December 9, 2026
• Final Outcomes Publication: Results will be published on January 29, 2027

Importantly, medicines like Ocrevus and Kesimpta will remain available throughout the review process, and there is no need for patients to change their treatment because of the review.

What Does MS Australia Want From This Review?

MS Australia, the peak advocacy organization for people with multiple sclerosis in the country, has outlined clear priorities for the review process. The organization welcomes the structured, evidence-based approach but emphasizes that MS is complex and highly individual, meaning no single treatment works for every person or at every stage of the disease.

MS Australia is advocating for the review to recognize several key principles:

• Diversity of MS: Acknowledge that multiple sclerosis presents differently in different people and requires personalized treatment approaches rather than one-size-fits-all solutions
• First-Line Access: Ensure patients have access to a broad range of PBS-listed medicines from the start of treatment, including high-efficacy options
• Treatment Differences: Properly evaluate differences between medications, including their effectiveness, safety profiles, how they are administered, and which patients they suit best
• Lived Experience: Keep the voices and experiences of people living with MS and their specialist clinicians central to decision-making
• Treatment Stability: Support stable and affordable access to medications now and in the future, without unnecessary disruption or delays in treatment

MS Australia stated that it welcomes a structured, evidence-based review that includes the voices of people living with MS and their clinicians, and will participate constructively while continuing to advocate strongly for affordable, dependable access to the full range of effective MS treatments.

What Should MS Patients Do Right Now?

If you are currently taking an MS medication, there is no immediate action required. Medicines remain available while the review is underway, and treatment should continue as prescribed. However, if you have questions or concerns about your medication, MS Australia recommends speaking with your neurologist, MS nurse, or treating healthcare professional.

MS Australia understands how important treatment certainty and choice are to people living with MS and has committed to keeping the community informed as consultation details are confirmed and as the review progresses.

What Else Is Happening in MS Research?

Beyond the PBAC review, MS research in Australia is advancing on multiple fronts. MS Australia is investing in early-stage research through its mid-year grants program, supporting promising ideas and early-career researchers to drive innovation in MS treatment and understanding. One funded project at The Florey Institute of Neuroscience and Mental Health is investigating how the brain naturally produces myelin, the protective coating around nerve fibers that is damaged by multiple sclerosis. This research into myelin repair represents a fundamental approach to addressing the root cause of MS-related disability.

The combination of the PBAC's systematic review of current treatments and ongoing research into new repair mechanisms reflects a comprehensive approach to improving outcomes for Australians living with MS. As the review unfolds over the coming months, patients and clinicians will have opportunities to contribute their perspectives on what works best in real-world practice.